A Phase 2 Study of ASONEP™ to Treat Unresectable and Refractory Renal Cell Carcinoma

A Phase 2 Study of ASONEP™ to Treat Unresectable and Refractory Renal Cell Carcinoma

Sponsors and Collaborators
Lpath, Inc.

Contact
Sumanta K Pal, MD
626-256-4673
spal@coh.org

Principal Investigator
France LaPierre-Holme, Executive Director of Development at Lpath

ClinicalTrials.gov Identifier
NCT01762033

Loading links....
You must be a registered member of Renal and Urology News to post a comment.

Sign Up for Free e-newsletters